Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 2/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6529925 | 0.98 | ACVR1 (0.41) | ACVR1BMPR1BBMPR1AACVRL1POLB | |
| SCHEMBL26476507 | 0.81 | PKM (0.55) | ACVR1BMPR1BBMPR1AACVRL1POLB | |
| SCHEMBL31251202 | 0.81 | MEN1 (0.50) | POLBMEN1KMT2APKMMAPT | |
| SCHEMBL13993447 | 0.81 | MEN1 (0.50) | POLBMEN1KMT2APKMMAPT | |
| SCHEMBL22667344 | 0.79 | ALDH1A1 (0.50) | ACVR1BMPR1BBMPR1AACVRL1POLB | |
| SCHEMBL13234017 | 0.79 | BMPR1B (0.40) | ACVR1BMPR1BBMPR1AACVRL1MEN1 | |
| SCHEMBL5862203 | 0.79 | ATAD2 (0.47) | MEN1KMT2APKMCNR1GPR55 | |
| SCHEMBL30954700 | 0.79 | OPRL1 (0.48) | ACVR1BMPR1BBMPR1AACVRL1POLB | |
| SCHEMBL21032697 | 0.78 | PKM (0.39) | ACVR1POLBNOX1MEN1KMT2A | |
| SCHEMBL2488961 | 0.78 | OPRL1 (0.48) | POLBMEN1KMT2ANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY | 2004-09-09 | — | — | US | claimed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119604493-A | Heterocyclic compounds as BCL6 modulators useful as ligand-directed degradants | 细胞基因公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4514473-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20070167444-A1 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| US-7012088-B2 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1632477-A1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | PHARMACIA & UPJOHN COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | ACVR1 2168/4885BMPR1B 735/4885BMPR1A 832/4885 |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | TRPV1, TRPV2, TRPV3 | ACVR1 1535/4885BMPR1B 888/4885BMPR1A 558/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | ACVR1 2168/4885BMPR1B 735/4885BMPR1A 832/4885 |
| US-20070167444-A1 | Benzamide derivative or salt thereof | TRPV1, BDKRB1, BDKRB2 | ACVR1 893/4885BMPR1B 648/4885BMPR1A 308/4885 |
| US-20040176610-A1 | Indolone oxazolidinones and derivatives thereof | OXA1L, IDO1, NDUFS7 | ACVR1 4133/4885BMPR1B 3393/4885BMPR1A 3507/4885 |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | ACVR1 2168/4885BMPR1B 735/4885BMPR1A 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.